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Abstract Dedifferentiation, migration, and proliferation
of resident vascular smooth muscle cells (SMCs) are key
components of neointima formation after vascular injury.
Activation of signal transducer and activator of transcrip-
tion-3 (STAT3) is suggested to be critically involved in this
process, but the complex regulation of STAT3-dependent
genes and the functional signiﬁcance of inhibiting this
pathway during the development of vascular proliferative
diseases remain elusive. In this study, we demonstrate that
STAT3 was activated in neointimal lesions following wire-
induced injury in mice. Phosphorylation of STAT3 induced
trans-activation of cyclin D1 and survivin in SMCs in vitro
and in neointimal cells in vivo, thus promoting proliferation
and migration of SMCs as well as reducing apoptotic cell
death. WP1066, a highly potent inhibitor of STAT3 signal-
ing, abrogated phosphorylation of STAT3 and dose-depen-
dentlyinhibitedthefunctionaleffectsofactivatedSTAT3 in
stimulated SMCs. The local application of WP1066 via a
thermosensitive pluronic F-127 gel around the dilated
arteries signiﬁcantly inhibited proliferation of neointimal
cells and decreased the neointimal lesion size at 3 weeks
afterinjury.EventhoughWP1066applicationattenuatedthe
injury-induced up-regulation of the chemokine RANTES at
6 h after injury, there was no signiﬁcant effect on the accu-
mulation of circulating cells at 1 week after injury. In con-
clusion, these data identify STAT3 as a key molecule for the
proliferative response of SMC and neointima formation.
Moreover, inhibition of STAT3 by the potent and speciﬁc
compound WP1066 might represent a novel and attractive
approach for the local treatment of vascular proliferative
diseases.
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Introduction
Inﬂammation and the subsequent activation of vascular
smooth muscle cells (SMCs) are key components in the
pathogenesis of vascular diseases, such as atherosclerosis,
post-angioplastyrestenosis,orveinbypassgraftfailure[12].
In response to pro-inﬂammatory stimuli, medial SMCs
secrete various chemotactic cytokines, leading to the accu-
mulation of leukocytes to the vessel wall [44]. During the
developmentofvasculardiseases,thechemokinesRANTES
(regulated upon activation, normal T-cell expressed, and
secreted), stromal-cell-derived factor (SDF)-1, or monocyte
chemotactic protein (MCP)-1 are considered to be key
components for the recruitment of circulating cells to the
vascular lesion site. The leukocytes in turn secrete various
growthfactorsandinducethede-differentiationofquiescent
and ‘‘contractile’’ SMCs into a ‘‘synthetic’’ phenotype [8].
De-differentiatedSMCsarehighly proliferativeandmigrate
toward the luminal side of the vessel, thus leading to a
stenotic process, which results in the development of a ne-
ointimallesion[28,41].Moreover,theup-regulationofanti-
apoptotic genes in neointimal SMCs leads to increased cell
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Therefore, a detailed understanding of the signaling mech-
anisms involved in the activation of SMCs is critical for the
development of new and selective treatment strategies for
vascular proliferative diseases [9].
The activation of the signal transducer and activator of
transcription-3 (STAT3) by the Janus kinase-2 (JAK2)
regulates gene expression in various biological processes,
including proliferation, cell survival, and inﬂammation
[16]. JAK2-dependent phosphorylation of STAT3 is
induced in SMCs in response to various growth factors and
cytokines, including platelet-derived growth factor
(PDGF)-BB, angiotensin II, or interleukin (IL)-6 [27, 38].
The phosphorylation of STAT3 leads to the dimerization
and the translocation of the transcription factor into the
nucleus, where it trans-activates several target genes
involved in proliferation and cell survival [18]. In different
tumor cell lines, the up-regulation of cyclin D1 and sur-
vivin has been shown to be dependent on STAT3 activation
[20, 25]. Although cyclin D1 controls the regulation of cell
cycle genes and thus cell proliferation, survivin represents
a member of the inhibitor of apoptosis protein (IAP) gene
family that blocks activation of effector caspases in dif-
ferent apoptotic pathways. Even though the JAK2/STAT3
pathway has been implicated in vascular proliferative dis-
eases, the various STAT3 target genes have barely been
characterized in activated SMCs in vitro and in vivo [35,
38]. During cardiac hypertrophy and heart failure, STAT3
signaling contributes to cardioprotection by promoting
cardiomyocyte survival via the interleukin (IL)-6/STAT3
axis and transcriptional regulation [3, 14]. In the process of
post-conditioning, however, the cardioprotective effects of
STAT3 are rather independent of gene regulation, but due
to its inhibitory effect on the opening of mitochondrial
permeability transition pores [4, 17].
In this study, we investigated the impact of WP1066, a
highly potent inhibitor of JAK2/STAT3 signaling, on
vascular SMCs and aimed to further understand the
mechanisms and downstream targets of STAT3 activation.
Although the parent compound AG490 only blocks phos-
phorylation of JAK2, WP1066 has also been described to
disrupt the JAK2 protein and to block STAT3 signaling
with an increase greater than ten-fold in potency compared
to AG490 [13, 19]. Despite the promising in vitro results of
STAT3-inhibition with AG490 or related molecules, these
compounds exerted only limited efﬁcacy in tumor models
in vivo [19, 35]. In contrast, the novel and highly potent
agent WP1066 is the only STAT3-targeting compound that
showed potent in vivo efﬁcacy in these models. Immuno-
histochemical staining of excised tumors revealed that
phosphorylated (p)-STAT3 levels remained inhibited in the
WP1066 treatment group up to 3 weeks after systemic
WP1066 injection [19]. Thus, WP1066 represents an
attractive compound that allows speciﬁc and highly potent
targeting of STAT3-activation in vivo and therefore might
represent an exciting novel tool for therapeutic strategies to
prevent vascular proliferative diseases.
Materials and methods
Cell culture, detection of proliferation, migration,
apoptosis, cell necrosis, and STAT3 promoter-binding
Human coronary artery SMCs were purchased from Lonza
(Cologne, Germany) and cultured in optimized growth med-
ium supplemented with 5 % FCS, 0.5 ng/ml epidermal
growthfactor,2 ng/mlbasicﬁbroblastgrowthfactor,5 lg/ml
insulin (PromoCell, Heidelberg, Germany), according to the
supplier’sprotocol.Cellsbetweenpassages3and6wereused
for all experiments.
Quantiﬁcation of SMC proliferation was assessed by
using a BrdU assay as previously described (Cell prolif-
eration ELISA, Roche, Mannheim, Germany) [33].
Migration of SMC was determined in a modiﬁed Boyden
chamber assay (Corning Costa Corp., Koolhovenlaan,
Netherlands), apoptosis was assessed by TUNEL-based
ELISA assay (cell death detection assay, Roche), and
necrosis by trypan blue exclusion as previously described
[33]. (E)-3(6-bromopyridin-2-yl)-2-cyano-N-((S0-1-phen-
ylethyl)acryl-amide), or WP1066, was purchased from
Sigma-Aldrich (Munich, Germany) and dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich). STAT3 pro-
moter-binding was assessed by the use of a STAT3-speciﬁc
DNA-binding ELISA (TransAM
TM, Active Motiv, via
THP Medical Products, Wien, Austria) according to the
manufacturer’s instructions.
Preparation of cellular lysates and immunoblot analysis
Protein extraction and semi-quantitative analysis of pro-
teins by western blotting was performed as previously
described [5]. In brief, the cleared supernatant from lysates
was run on polyacrylamide gel and blotted onto nitrocel-
lulose by a commercial dry blotting system (Invitrogen,
Frankfurt, Germany). After blocking, the blots were incu-
bated with the primary antibody for 24 h at 4 C. Primary
antibodies were used for STAT3 (Cell Signaling Tech-
nology, Danvers, MA, USA), phosphorylated-(p)-STAT3
(Cell Signaling Technology), RANTES (Epitomics, Bur-
lingame, CA, USA), and b-tubulin (Epitomics). The pro-
teins were then detected by enhanced chemiluminescence
(ECL?, Amersham) after labeling with a horseradish
peroxidase-labeled secondary antibody according to the
manufacturer’s instructions (GE Healthcare, Chalfont St.
Giles, Great Britain).
Page 2 of 12 Basic Res Cardiol (2012) 107:261
123Real-time quantitative RT-PCR
Isolation of total RNA and synthesis of cDNA were per-
formed using commercial kits (RNeasy and QuantiTect
Rev. Transcription Kit, Qiagen, Hilden, Germany). Real-
time PCR was performed on a Stratagene MX300 quanti-
tative PCR System (Stratagene MxPro, La Jolla, CA) using
the SYBR Green PCR mix (PeqLab, Erlangen, Germany).
Primers were as follows: human STAT3 forward 50-TTT
GTC AGC GAT GGA GTA CG-30, reverse 50-GCT GCA
ACT CCT CCA GTT TC-30; mouse STAT3 forward 50-
CAA TAC CAT TGA CCT GCC GAT-30, reverse 50-GAG
CGA CTC AAA CTG CCC T-30; human cyclin D1 forward
50-CCG TCC ATG CGG AAG ATC-30, reverse 50-ATG
GCC AGC GGG AAG AC-30; mouse cyclin D1 forward 50-
TGT GCG CCC TCC GTA TCT TAC-30, reverse 50-TTC
TGC TCC TCA CAG ACC TCC A-30; human survivin
forward 50-TGC TGT GGA CCC TAC TGG GTT-30,
reverse 50-TGT CTG GGC AGA TGG CTG TTG-30;
mouse survivin forward 50-ACC GAG AAC GAG CCT
GAT TTG G-30, reverse: 50-GCT TTC TAT GCT CCT
CTA TCG GGT T-30; human RANTES forward 50-ATC
AAG ACA GCA CGT GGA CCT C-30, reverse 50-TGT
GGT GTC CGA GGA ATA TGG G-30; mouse RANTES
forward 50-TGC CGC GGG TAC CAT GAA GAT-30,
reverse 50-TCC GAG CCA TAT GGT GAG GCG-30;
human and mouse glyceraldehyde-3-phosphate dehydro-
genases (GAPDH) forward 50-TGC ACC ACC AAC TGC
TTA GC-30, reverse 50-GGC ATG GAC TGT GGT CAT
GAG-30. For quantiﬁcation of gene expression changes, the
DDCt method was used to calculate relative fold changes
normalized to GAPDH. All analyses were performed in
triplicate, and either the DNA template or the reverse
transcriptase was omitted for control reactions.
Mouse femoral artery injury model
All in vivo experiments were performed on adult male
C57/BL6 mice purchased from Charles River (Sulzfeld,
Germany). The mice were anesthetized with 150 mg/kg
body weight ketaminehydrochloride (Ketanest, Pharmacia/
Pﬁzer, Mannheim, Germany) and 0.1 mg/kg body weight
xylazinehydrochloride (Rompun 2 %, Bayer, Leverkusen,
Germany). The dilation of the femoral artery was per-
formed by inserting a straight spring wire (0.38 mm in
diameter; Cook, Bloomington, IN, USA) for *10 mm
towards the iliac artery, as previously described [32].
Immediately after dilation, the artery was covered with
50 ll of a 25 % thermosensitive pluronic F-127 gel con-
taining WP1066 (200 lg/ml) or vehicle (DMSO) only. The
arteries were excised at the time-points indicated in the
results section. The arteries dedicated to morphometric
analyses and immunohistochemistry were ﬁxed in 4 %
paraformaldehyde (PFA) and embedded in Tissue Tek
OCT embedding medium (Sakura Finetek Europe B. V.,
Zoeterwoude, The Netherlands). The arteries were snap-
frozen and stored at -80 C until sectioning. The vessels
dedicated to mRNA and protein analysis were perfused
with phosphate buffered saline (PBS), microscopically
rasped from adventitial as well as endothelial tissue and
chopped using tissue grinder (Kimble-Chase, Vineland, NJ,
USA). The mice intended for analysis of the integrity of the
endothelial layer were injected with 0.5 ml of 0.5 % Evans
blue dye (Sigma-Aldrich) in PBS into the tail vein. At
10 min after injection, mice were perfused with 4 % PFA
and the femoral artery was excised and opened longitudi-
nally to expose the luminal surface. All procedures
involving experimental animals were approved by the
Institutional Committee for Animal Research of the Gies-
sen University and complied with the Guide for the
Care and Use of Laboratory Animals (NIH publication
No. 86-23, revised 1985).
Morphometric analysis
The whole artery was cut in 6-lm serial sections, and six
cross-sections from regular intervals throughout the artery
were stained with hematoxylin–eosin. For morphometric
analyses, Metamorph Imaging 7.0 software (Molecular
Devices, Downingtown, PA, USA) was used to measure
external elastic lamina, internal elastic lamina, and lumen
circumference as well as to calculate medial and neointi-
mal area.
Immunoﬂuorescence and immunohistochemistry
After ﬁxation and rehydration, the slides were pre-incu-
bated with 10 % normal goat serum (Zymed
 Laboratories
Inc., San Francisco, CA, USA) and then incubated with
antibodies against a-SMA (Sigma-Aldrich, Munich, Ger-
many), CD31 (BD Pharmingen, Franklin Lakes, NJ, USA),
CD45 (BD Pharmingen), CD68 (Serotec, Oxford, UK),
STAT3 (Cell Signaling Technology, Danvers, MA, USA),
von-Willebrand-factor (Dako, Glostrup, Denmark),
p-STAT3 (Cell Signaling Technology), or RANTES (R&D
Systems, Wiesbaden, Germany). Ensuing incubations were
carried out with Alexa Fluor
-488 or Alexa Fluor
-546-
coupled secondary antibodies (Molecular Probes, Eugene,
Oregon, USA) and counterstained with nuclear 4.6-diami-
dino-2-phenylindole (DAPI) (Linaris, Wertheim, Ger-
many). Monoclonal antibodies to a-SMA were labeled
directly with Cy3. The detection of STAT3 and p-STAT3
required membrane permeabilization using Triton X-100
(0.2 %, Bio-Rad, Munich, Germany) or heat-mediated
antigen retrieval by incubating the slides in sodium citrate
buffer for 10 min at 90 C. Staining for proliferating cell
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staining kit (Invitrogen, Frankfurt, Germany). The number
of apoptotic SMCs was quantiﬁed by terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) according to the supplier’s instructions (in situ
cell death detection kit, Roche). Re-endothelialization was
quantiﬁed by estimating the lumen coverage on a scale
from 0 to 6 (0, no coverage; 6 complete coverage). Neg-
ative controls were conducted by substituting the primary
antibody with an appropriate species- and isotype-matched
control antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA).
Statistical analysis
Data between the study groups were analyzed with 1-way
ANOVA (Systat, Erkrath, Germany) followed by pair-wise
multi-comparison using the Holm-Sidak method. Statisti-
cally signiﬁcant differences in normally distributed vari-
ables between two groups were determined by using the
Student’s t test. A probability value\0.05 was considered
statistically signiﬁcant for all comparisons.
Results
STAT3 is phosphorylated and up-regulated
in the developing neointimal lesion
In a mouse model of wire-induced injury of the femoral
artery, a neointimal lesion usually develops within
14–21 days after dilation [10]. Real-time PCR of the neo-
intimal tissue revealed signiﬁcantly higher levels of STAT3
mRNA at both 14 days and 21 days after dilation compared
to non-dilated control arteries (4.28 ± 0.39-fold up-regu-
lation at 21 days after injury compared to uninjured arteries,
n = 6, *P\0.05, Fig. 1a). The up-regulation of total
STAT3 protein levels as well as an increase in p-STAT3
was conﬁrmed by western blotting of excised neointimal
lesions compared to uninjured arteries (n = 6, *P\0.05,
Fig. 1b). The increase in p-STAT3 (3.6 folds) was more
prominent than the increase in total STAT3 protein levels
(1.5 folds) in the developing neointimal lesion (Fig. 1c, d).
Immunohistochemical staining for p-STAT3 conﬁrmed the
western blotting results and revealed signiﬁcant amounts of
the activated form of the transcription factor within the
nuclei of neointimal cells (Fig. 1e). In contrast, p-STAT3
was hardly expressed in non-injured arteries (Fig. 1f).
Importantly, co-staining of p-STAT3 with smooth muscle
marker proteins (a-smooth muscle actin) revealed high
expression levels of p-STAT3 in neointimal SMCs and
also of smooth muscle-like cells in the adventitial layer
(Suppl. Fig. 1a). Within the neointimal lesion, however,
STAT3/p-STAT3 expression was also detectable in areas
with distinctive staining for monocytes/macrophages
(CD68), especially within the medial layer (Suppl. Fig. 1b).
As a negative control, an appropriate species- and isotype-
matched control antibody was used (Fig. 1f).
Survivin and cyclin D1 are STAT3-dependent target
genes in stimulated SMCs in vitro and in neointimal
cells in vivo
Mitogenic stimulation of SMCs resulted in phosphorylation
of STAT3 in vitro, as shown by western blotting analysis at
10 min after treatment. Concomitantly, we detected phos-
phorylation of JAK2 after stimulation of the cells, which is
a prerequisite for the subsequent phosphorylation of cyto-
solic STAT3 proteins. The phosphorylation of JAK2/
STAT3 could be prevented following the administration of
WP1066, a speciﬁc and potent STAT3 inhibitor (Fig. 2a)
[14]. At 4 and 8 h after stimulation, we detected a signif-
icant up-regulation of STAT3 mRNA levels in SMCs in
vitro. This up-regulation of STAT3 could be conﬁrmed on
the protein level at 8 and 12 h after stimulation (Suppl.
Fig. 2). WP1066 potently prevented the phosphorylation of
STAT3 but had no effect on the regulation of STAT3
mRNA or protein levels at early time-points after stimu-
lation (data not shown). Since phosphorylation of STAT3
as the principle mechanism of STAT3 signaling is critically
involved in proliferation and cell survival [16], we aimed
to identify target genes of p-STAT3 that mediate the
functional effects of the transcription factor in SMCs. We
found the mRNA levels of both cyclin D1 and survivin to
be signiﬁcantly up-regulated in stimulated SMCs at 18 and
24 h and within the neointimal lesion of dilated arteries, as
determined by real-time PCR (Fig. 2b, c and Suppl.
Fig. 3). A DNA-binding ELISA assay revealed an
enhanced binding of STAT3 to corresponding promoter-
binding sites in SMCs after stimulation with growth med-
ium (Fig. 3a). Importantly, the speciﬁc STAT3 inhibitor
WP1066 dose-dependently prevented DNA-binding of
STAT3 to its promoter regions. At WP1066 concentrations
of 10 lM, the promoter-binding of STAT3 was almost
completely prevented (Fig. 3a). Consequently, the trans-
activation of the STAT3 target genes cyclin D1 and sur-
vivin was effectively blocked by WP1066 in growth
medium-stimulated SMC, as determined by qPCR at 24 h
after stimulation (Fig. 3b, c).
WP1066 abrogates the functional effects of growth
medium stimulation on SMC
To evaluate the functional effects of STAT3 inhibition on
proliferation, migration, and apoptosis of SMCs, human
coronary SMCs were incubated with growth medium in the
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WP1066. Application of WP1066 dose-dependently pre-
vented the increase in SMC cell numbers after incubation
with growth medium for 48 h (cell numbers increased to
308.5 ± 12 % vs. 147.5 ± 12 % at 10 lM WP1066;
n = 4; *P\0.05; Fig. 4a). The results from a BrdU
incorporation assay showed that proliferation of SMCs was
dose-dependently attenuated and almost completely pre-
vented at concentrations of 10 lM WP1066 (Fig. 4b).
Moreover, WP1066 dose-dependently inhibited the
migration of SMCs as determined by a modiﬁed Boyden
chamber assay (78.08 ± 9.1 vs. 23.17 ± 4.33 cells/high
power ﬁeld at 10 lM WP1066; n = 4; *P\0.05; Fig. 4c).
The reduction in cell numbers was due to both an inhibition
of SMC proliferation and an increase in the percentage of
apoptotic (TUNEL?) SMCs (OD 0.099 ± 0.024 vs. OD
0.793 ± 0.148 at 10 lM WP1066; n = 4; *P\0.05;
Fig. 4d). The increase in apoptotic cell death of SMCs was
observed under basal conditions as well as under mitogenic
conditions (Suppl. Fig. 4a). There was no effect of
WP1066 on cell necrosis at 2.5, 5, and 10 lM, as deter-
mined by Trypan blue exclusion. However, we observed
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Fig. 1 Phosphorylation and up-
regulation of STAT3 during
neointima formation. a Real-
time PCR revealed a signiﬁcant
up-regulation of STAT3 mRNA
levels in the dilated artery at 2
and 3 weeks after dilation
(*P\0.05, n = 4). b–d
Western blotting experiments
showed a signiﬁcant up-
regulation of total STAT3 (1.5
fold) and phosphorylated (p)-
STAT3 (3.6 fold) at 3 weeks
after dilation.
e Immunohistochemical
staining for p-STAT3 at
3 weeks after dilation revealed
that the transcription factor is
activated and located within the
nucleus during the development
of a neointimal lesion. The
neointimal lesion (asterisk) and
the medial layer are indicated
(arrowheads indicate the auto-
ﬂuorescent internal and external
elastic laminae deﬁning the
medial layer). f In contrast,
there was virtually no p-STAT3
detectable in uninjured arteries.
g A species- and isotype-
matched control antibody was
used as a negative control. The
internal elastic lamina shows
strong auto-ﬂuorescence
(arrowhead)
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123toxic effects of WP1066 at 20 lM or higher concentra-
tions, which signiﬁcantly increased necrotic cell death of
SMCs in vitro (Suppl. Fig. 4b).
WP1066 prevents neointima formation in vivo
To determine whether our in vitro results on the effects of
WP1066 were reproducible in vivo, we dilated the femoral
artery and applied 50 ll of a thermosensitive pluronic F-127
gelcontainingWP1066(200 lg/ml)orvehiclecontrolaround
the dilated region of the artery [32]. At 21 days after wire-
induced injury, a signiﬁcant concentric neointimal lesion had
developed, whereas the medial layer could be clearly deﬁned
by the internal and external elastic laminae (Fig. 5a). In
WP1066-treated mice, the neointimal lesion size was
signiﬁcantlyreducedat21 daysafterdilationoftheartery(NI/
mediaratio0.64 ± 0.29vs.1.76 ± 0.51inthecontrolgroup,
n = 6; *P\0.05; Fig. 5a). In accordance with our in vitro
data, we detected a reduced expression p-STAT3 within the
vessel wall of WP1066 treated mice, whereas the neointimal
lesion in the vehicle control showed a robust expression of
p-STAT3 within the neointimal cellular mass (Fig 5b).
WP1066 inhibits proliferation and increases apoptotic
rates of neointimal SMC
Further immunohistochemical evaluation of the neointimal
lesions revealed that WP1066 reduced neointima formation
by inhibiting SMC proliferation and increasing the per-
centage of apoptotic cells within the vascular wall. In the
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Fig. 3 WP1066 abrogates nuclear binding of STAT3 and expression
of its target genes. a SMCs were grown in the absence or presence of
different concentrations of WP1066 for 24 h and STAT3 promoter-
binding was assessed. b, c Real-time PCR revealed that mRNA levels
of cyclin D1 and survivin were found to be abrogated in the presence
of WP1066 (*P\0.05, n = 4)
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123WP1066-treated group, the proliferation of neointimal and
medial cells was signiﬁcantly reduced at 21 days after
injury, as determined by the percentage of PCNA-positive
cells within the vascular wall (9.7 ± 3 % vs. 4.0 ± 2.16 %
PCNA-positive cells in arteries from mice treated with
WP1066, n = 6, *P\0.05; Fig. 6a).
In contrast, the percentage of apoptotic cells was sig-
niﬁcantly increased in the dilated arteries after treatment
with WP1066, as determined by quantiﬁcation of TUNEL-
positive cells in situ (3.9 ± 2.22 % vs. 13.4 ± 4.64 %
TUNEL-positive cells in arteries from mice treated with
WP1066, n = 6, *P\0.05; Fig. 6b). Re-endothelializa-
tion of the dilated arteries was mostly complete and did not
show a signiﬁcant difference between the vehicle-treated
group and the WP1066-treated group at 21 days after
injury (Suppl. Fig. 5). In addition, there were no deleteri-
ous effects of local WP1066 application on the intact
endothelial layer of uninjured arteries (Suppl. Fig 6).
Effects of WP1066 on RANTES expression
and leukocyte accumulation after vascular injury
The chemokine RANTES mediates leukocyte accumula-
tion and its regulation after vascular injury has been
described to be dependent on STAT3 signaling [22]. At 6 h
after dilation, we found RANTES mRNA levels to be
signiﬁcantly up-regulated compared to uninjured femoral
arteries, as determined by qPCR of extracted vessels. This
profound up-regulation of RANTES on the mRNA level
could be conﬁrmed by immunohistochemical staining on
the protein level. Importantly, application of WP1066
immediately after injury prevented transcription of RAN-
TES (P\0.05, n = 6) and also led to reduced immuno-
reactivity of RANTES within the vessel wall (Fig. 7a). At
6 h after injury, we found only low numbers of leukocytes
in the peri-vascular tissue and very few adhering at the
arterial lesion site (data not shown).
The effects of WP1066 on the accumulation of leuko-
cytes were further investigated at 1 week after injury (the
time-point of the peak inﬂammatory response in this injury
model). Indeed, in WP1066-treated mice, we found a
slightly reduced accumulation of CD45-positive cells at the
arterial lesion site. However, this effect was not statistically
signiﬁcant (Fig 7b). Importantly, peripheral blood cell
counts at 1 week after injury did not indicate any signiﬁ-
cant difference between the vehicle-treated group and the
WP1066-treated group in regard to circulating leukocytes,
erythrocytes, or platelets (Table 1, Suppl. Fig. 7).
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Fig. 4 WP1066 inﬂuences proliferation, migration and apoptosis of
stimulated SMCs. a SMCs were incubated with growth medium in the
absence or presence of different concentrations of WP1066 and total
cell number was evaluated after 48 h (*P\0.05, n = 4). b SMCs
were incubated with growth medium in the absence or presence of
different concentrations of WP1066 for 24 h in the presence of BrdU.
SMC proliferation is expressed as mean OD450 ± SEM as deter-
mined by anti-BrdU ELISA (*P\0.05, n = 4). c SMCs were added
to the upper side of gelatin-coated tissue culture inserts and allowed to
migrate for 6 h in the presence or absence of PDGF (20 ng/ml) or
different concentrations of WP1066. After microscopic evaluation of
inserts, the number of migrated cells was expressed as cells per high
power ﬁeld (cells/HPF) (*P\0.05, n = 4). d SMCs were incubated
in basal medium in the absence or presence of different concentra-
tions of WP1066 for 24 h, and apoptosis of SMCs was evaluated by a
TUNEL-based cell death detection ELISA (*P\0.05, n = 4)
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123Discussion
STAT3 is phosphorylated in response to growth factors and
cytokines in a variety of proliferating cell types, including
SMCs in vitro [16, 35]. We now provide the ﬁrst in vivo
data on elevated p-STAT3 levels in dilated mouse arteries,
leading to a profound up-regulation of cyclin D1 and sur-
vivin. Furthermore, we characterize the functional effects
of STAT3 phosphorylation in stimulated SMCs and show
that the speciﬁc inhibitor WP1066 dose-dependently blocks
STAT3 activation and the trans-activation of its target
genes cyclin D1 and survivin. As a proof of concept that
phosphorylation of STAT3 is crucial for the development
of vascular proliferative diseases, we show that the speciﬁc
STAT3 inhibitor WP1066 effectively prevents neointimal
lesion formation after wire-induced injury.
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Fig. 5 WP1066 prevents neointima formation in vivo. a Representa-
tive cross-sections of femoral arteries from control mice (left) or mice
treated with WP1066 (right) are shown at 3 weeks after dilation. The
intima/media (I/M) ratio from control mice (left) or mice treated with
WP1066 (right) was quantiﬁed at 3 weeks after injury (n = 6,
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hematoxylin (blue). The number of proliferating (PCNA positive)
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cells per section (n = 6, *P\0.05). b Representative cross-sections
of femoral arteries from control mice (left) or mice with WP1066
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TUNEL positive cells per section by the total cell number per section
(n = 6, *P\0.05)
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123Proliferation, migration, and apoptosis of SMC are all
fundamental components in the development of a neointi-
mal lesion [9, 12]. In the process of neointima formation,
the STAT3 target gene cyclin D1 does not only represent a
key regulator of cell cycle genes but also of SMC migration
and thus cell motility [21, 38]. Moreover, it has recently
been shown that anti-apoptotic genes are up-regulated in
neointimal SMCs and that blockade of these anti-apoptotic
genes is effective in preventing neointima formation [29].
Interestingly, survivin has been identiﬁed as a critical
regulator of cell survival in SMC in vivo, and disrupting
the survivin pathway effectively suppresses neointima
formation after vascular injury [2]. Hence, WP1066
inhibits neointima formation by two additive mechanisms:
there is a beneﬁcial effect from reducing the proliferation
and migration of SMCs via preventing the expression of
cyclin D1. Furthermore, the neointimal cellular mass is
reduced by increased apoptosis of SMCs due to a reduced
survivin expression. Although our analysis of STAT3-
dependent target genes is limited, we presume that cyclin
D1 and survivin, acting via different mechanisms, repre-
sent two key components with a high functional signiﬁ-
cance on neointima formation.
In the recent reports, STAT3 activation could be linked
to functional effects on neointimal cells, and inhibition of
STAT3 signaling by AG490 was shown to antagonize these
effects [35, 36]. In our experiments, we used WP1066, a
STAT3 inhibitor that is signiﬁcantly more active and
potent compared to its parent compound AG490 [11, 13].
Even though AG490 routinely exerts potent in vitro
activity, AG490 has not consistently been demonstrated to
have a potent in vivo effect in animal models, except when
applied in very high (and potentially toxic) doses [19, 35].
In contrast, WP1066 has been shown to speciﬁcally prevent
STAT3 phosphorylation at low doses in tumor models up
to 3 weeks after the last injection of the inhibitor [19]. In
addition to its high potency, WP1066 thus exerts its spe-
ciﬁc effects on vascular SMCs over a long time-period
after arterial injury. Both of these characteristics are
absolutely mandatory for the successful use of a drug to
inhibit neointima formation in the clinical setting.
Inﬂammation is another key component of neointimal
lesion formation [15, 34]. The denudation of the endothe-
lium and the cell death of medial SMCs after vascular
injury are followed by the secretion of cytokines and
chemokines, leading to the recruitment of leukocytes to the
vascular lesion [40]. Importantly, the secretion of the
chemokine RANTES from SMCs at several hours after
vascular injury is dependent on STAT3 expression [22].
Even though we could show that inhibiting STAT3 sig-
naling prevents the up-regulation of RANTES at 6 h after
injury, the effect on the accumulation of leukocytes at
1 week after dilation was only moderate. A complex net-
work of cytokines and chemokines is involved in the
recruitment of circulating cells, including RANTES, MCP-
1, and SDF-1a (CXCL12) [24, 43]. Although SDF-1a and
RANTES are highly expressed within the medial layer of
the dilated arteries at 6 h after injury, the expression of
SDF-1a and RANTES within the medial layer rapidly
decreases at later time-points after injury [22, 42]. Instead,
platelets adhering to the disrupted endothelial layer repre-
sent a major source of chemokines and have been shown to
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Fig. 7 WP1066 prevents up-regulation of RANTES after vascular
injury but does not signiﬁcantly reduce the accumulation of circu-
lating cells to the lesion. a Representative cross-sections of femoral
arteries at 6 h after dilation show that the up-regulation of RANTES
after injury is inhibited by WP1066. Real-time PCR of femoral artery
extracts conﬁrm the up-regulation of RANTES on the mRNA level at
6 h after injury and the prevention by WP1066. b In contrast, the
accumulation of leukocytes at 1 week after dilation did not show a
signiﬁcant difference between control mice (left) and mice after
WP1066 application (right)( n = 6, *P\0.05)
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123carry high amounts of RANTES mRNA [6, 30]. The
inhibition of platelet-derived RANTES by systemic injec-
tion of speciﬁc RANTES receptor antagonists has been
shown to reduce macrophage inﬁltration and neointimal
lesion formation [31]. However, in our model, WP1066
was applied around the adventitial layer and thus did not
directly target platelet-derived RANTES. Therefore, the
effects of WP1066 on the initial secretion of RANTES by
SMCs do not signiﬁcantly reduce the accumulation of
leukocytes in our model. Instead, we provide evidence that
WP1066 impedes the proliferative response of vascular
SMCs by inhibiting phosphorylation of STAT3 and thus
trans-activation of cyclin D1 and survivin. This is further
supported by the detection of WP1066 speciﬁc effects for
up to 3 weeks after application of the inhibitor in a tumor
model [19]. Our immunohistochemical studies conﬁrm that
WP1066 was very effective in reducing phosphorylation of
STAT3 and the proliferative response of SMCs within the
vessel wall for at least 3 weeks after injury. Interestingly,
we also detected adventitial cells expressing p-STAT3
during the process of neointima formation (Suppl. Fig 1).
Since clonal expansion of (myo-)ﬁbroblasts and also peri-
vascular progenitor cells have been described to contribute
to neointimal lesion formation, it is very likely that
WP1066 does not only inhibit proliferation/migration of
genuine SMCs but also of adventitial (progenitor-)cells
[23].
Even though the process of re-endothelialization was not
affected at 21 days after injury, there is accumulating evi-
dence that STAT3 also inﬂuences the proliferation of
endothelial cells [1, 39]. Therefore, application of WP1066
could possibly delay re-endothelialization of the dilated
vessel, so that a prolonged anti-thrombotic therapy might be
necessary to abrogate this potential side effect of WP1066
[9]. However, our data indicate that application of WP1066
does not impair endothelial integrity in neighboring or
uninjured vessel areas. Thus, WP1066 holds promise to
emerge as a promising agent for the treatment of vascular
proliferative diseases, because it effectively and simulta-
neously inﬂuences proliferation, migration, and apoptosis
of SMCs. Unfortunately, many substances that were shown
to affect SMC cell cycle entry, proteasome function, or
retention of lipids and proteoglycans, thereby blocking
neointima formation in animal models, failed to show
beneﬁcial effects in the clinical setting [7, 26, 33, 37].
However, as WP1066 is a very potent inhibitor with a
remarkable long-term inhibitory effect on the phosphory-
lation of STAT3 in vivo, this compound holds promise to be
effective in the clinical setting as well to prevent restenosis
when locally applied using drug-eluting stents or balloons.
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Table 1 Blood tests were performed at 1 week after injury, in order to analyze the systemic effects of WP1066
Control WP1066 P value
N 56
Leukocytes (10
9/L) 3.72 ± 1.14 3.28 ± 0.97 0.511
Erythrocytes (10
12/L) 8.94 ± 0.55 8.97 ± 0.69 0.537
Hemoglobin (g/L) 137.60 ± 9.40 131.67 ± 12.52 0.406
Hematokrit (L/L) 0.44 ± 0.04 0.44 ± 0.04 0.748
Mean corpuscular volume (fL) 49.60 ± 2.41 48.67 ± 1.63 0.464
Mean corpuscular hemoglobin (pg) 15.40 ± 0.85 14.68 ± 0.44 0.354
Mean corpuscular hemoglobin concentration (g/dL) 30.96 ± 1.51 30.17 ± 0.92 0.239
Platelets (10
9/L) 272.20 ± 89.19 513.17 ± 238.72 0.330
Eosinophils (10
9/L) 0.03 ± 0.06 0.01 ± 0.03 0.762
Segmented Neutrophils (10
9/L) 0.74 ± 0.41 0.54 ± 0.35 0.824
Basophils (10
9/L) 0.00 ± 0.00 0.00 ± 0.00 1.000
Lymphocytes (10
9/L) 2.98 ± 0.77 2.56 ± 0.88 0.760
Monocytes (10
9/L) 0.07 ± 0.14 0.06 ± 0.05 0.352
Creatinine (mg/dL) 0.10 ± 0.00 0.09 ± 0.04 0.762
Albumin (g/L) 22.75 ± 2.50 22.17 ± 3.06 0.760
Lactate dehydrogenase (U/L) 523.00 ± 97.97 458.40 ± 85.36 0.114
Aspartate transaminase (U/L) 142.00 ± 60.65 172.17 ± 61.93 0.469
Alanine transaminase (U/L) 25.50 ± 1.91 25.00 ± 4.15 0.830
There was no signiﬁcant difference between vehicle (DMSO) and WP1066 treated mice
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